openPR Logo
Press release

Whistleblower Escalates Against ROCHE and TRANSCOM After Continued Obstruction and Retaliation

11-12-2025 12:25 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Cambridge Samuel

Whistleblower Escalates Against ROCHE and TRANSCOM After

A protected whistleblower under Portugal's Law No. 93/2021 will escalate legal action against Transcom and Roche following months of systematic non-compliance with GDPR and whistleblower protection obligations.

Despite final deadlines expiring on 8 November (Transcom) and total silence from Roche - including from Global Privacy Office representative Viviana Aguirre - since 24 October 2025, both companies continue to withhold the missing August 20 meeting recording, refuse to justify unlawful redactions and omissions, and fail to establish mandatory Article 8 whistleblowing channels or remedy the retaliatory conduct. Non-compliance continues regarding:

-Full personal data required under Article 15 GDPR (including internal emails, support tickets, account metadata and Roche - Transcom correspondence related to the retaliatory account lockout of 20 August 2025)

-The mandatory confidential internal reporting channels required by Article 8 of Law No. 93/2021

-The audio recording of the 20 August 2025 meeting involving Transcom managers Philip Christopher Brunner, Raquel Joana Silva Sequeira and Maria Goreti Da Silva Batista Carmona Martins

-Direct contact details of Roche's Chief Group Compliance Officer, in direct violation of Roche's own publicly stated Non-Retaliation Policy

All attempts at amicable resolution have been exhausted. Formal proceedings are now being initiated with:

-Comissão Nacional de Proteção de Dados (CNPD) - repeated and aggravated GDPR violations

-Autoridade para as Condições do Trabalho (ACT) - failure to establish lawful whistleblowing channels and retaliation

-Ministério Público - criminal investigation into obstruction and retaliation against the companies and officials involved

-Civil courts - claims for material and non-material damages

Statement from Cambridge Samuel:

"Eleven weeks of documented obstruction, missed deadlines and deliberate silence leave no doubt: these are not administrative oversights - they are conscious attempts to suppress lawful rights. That ends now. Full accountability - legal, financial and public - begins this week."

Av. da Liberdade 110
1269-046 Lisboa, Portugal
+351 214 00 55 00

Sofia Goncalves / sofia.goncalves@cambridgesamuel.com

Cambridge Samuel is exploring collective legal options for employees facing workplace violations. If you've experienced unfair treatment, contact us at;

class-action@cambridgesamuel.com or at legal@cambridgesamuel.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Whistleblower Escalates Against ROCHE and TRANSCOM After Continued Obstruction and Retaliation here

News-ID: 4266118 • Views:

More Releases for Roche

Germany Hepatitis C Testing Market Size, Trends, Growth, Opportunities (2024-203 …
The dental handpiece market was valued at USD 106.8 million in 2019 and is projected to grow from USD 80.1 million in 2020 to USD 121.4 million in 2027, recording a CAGR of 6.1% during the forecast period (2024-2032). The Germany Hepatitis C Testing Market continues to grow as public health initiatives and advanced diagnostics play a pivotal role in managing the hepatitis C virus (HCV) epidemic. Germany's healthcare infrastructure is
Atezolizumab Market Size, Growth Opportunities 2031 by Key Manufacturer- Genente …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Atezolizumab Market size was valued at USD 2.68 Billion in 2023 and is expected to reach USD 7.86 Billion by the end of 2031 with a CAGR of 16.6% During the Forecast Period 2023-2031. The Atezolizumab Market presents significant opportunities driven by advancements in immuno-oncology, the growing prevalence of cancer, and the increasing demand for targeted cancer therapies. Atezolizumab is
Biomarker Testing Market | Agilent Technologies, Roche, ,
The global biomarker testing market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the biomarker testing market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Tumor Immunotherapy Market 2023 Comprehensive Analysis - AstraZeneca, Pfizer Inc …
Global Tumor Immunotherapy Market 2023 is the fresh report by Fior Markets that is formulated with the exact understanding of customer requirements. The report covers comprehensive market analysis, evaluation of findings, as well as assumptions taken from a variety of sources. The research report offers an in-depth look at the service providers operating in the global Tumor Immunotherapy market. According to the analyst, the market is going through a large
Tecentriq Market Analysis & Forecast 2021 - 2027|Roche, ,
Complete study of the global Tecentriq market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Tecentriq industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the researchers. They have also provided accurate
PEGylated Protein Therapeutics Market Competitive Analysis | Amgen, AstraZeneca, …
PEGylated Protein Therapeutics Market analysis document helps identify the latest growths, market shares, and policies employed by the major market players. In addition, this market study affirms the leading players across the globe in the PEGylated Protein Therapeutics Market and their key marketing dispositions and advertising enterprise have been highlighted to offer a clear understanding of the market. The major topics of this document can be listed as; Overview of